Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

PMID:
30165419
2.

Reality of the emetogenic level of irinotecan.

Garcia-Del-Barrio MA, Martin-Algarra S, Aldaz Pastor A.

Support Care Cancer. 2018 Oct;26(10):3441-3446. doi: 10.1007/s00520-018-4196-z. Epub 2018 Apr 21.

PMID:
29679139
3.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
4.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A.

Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523.

5.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, Martin-Algarra S; Spanish Melanoma Group (GEM).

Ann Transl Med. 2017 Oct;5(19):389. doi: 10.21037/atm.2017.08.10. Review.

6.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

7.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

8.

Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.

Martin-Romano P, Jurado M, Idoate MA, Arbea L, Hernandez-Lizoain JL, Cano D, Paramo JA, Martin-Algarra S.

J Med Case Rep. 2017 Apr 19;11(1):115. doi: 10.1186/s13256-017-1262-y.

9.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S; Spanish Melanoma Group.

Clin Transl Oncol. 2017 Jun;19(6):761-768. doi: 10.1007/s12094-016-1602-1. Epub 2017 Jan 4.

PMID:
28054320
10.

Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.

Viúdez A, De Jesus-Acosta A, Carvalho FL, Vera R, Martín-Algarra S, Ramírez N.

Crit Rev Oncol Hematol. 2016 May;101:193-206. doi: 10.1016/j.critrevonc.2016.03.013. Epub 2016 Mar 11. Review.

PMID:
27021395
11.

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.

Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E.

Clin Transl Oncol. 2016 Nov;18(11):1147-1157. Epub 2016 Mar 17.

PMID:
26983408
12.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S.

Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254.

13.

Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.

Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E.

Clin Transl Oncol. 2016 Oct;18(10):1044-50. doi: 10.1007/s12094-016-1484-2. Epub 2016 Jan 22.

PMID:
26801342
14.

Circulating melanoma exosomes as diagnostic and prognosis biomarkers.

Alegre E, Zubiri L, Perez-Gracia JL, González-Cao M, Soria L, Martín-Algarra S, González A.

Clin Chim Acta. 2016 Feb 15;454:28-32. doi: 10.1016/j.cca.2015.12.031. Epub 2015 Dec 24.

PMID:
26724367
15.

Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma.

Berrocal A, Espinosa E, Marín S, Malvehy J, Moreno D, Lozano MD, Martin-Algarra S, Lopez JA, Conill C, Rodriguez-Peralto JL.

Eur J Dermatol. 2015 Sep-Oct;25(5):392-403. doi: 10.1684/ejd.2015.2594. Review.

PMID:
26693633
16.

Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Buil-Bruna N, López-Picazo JM, Martín-Algarra S, Trocóniz IF.

Oncologist. 2016 Feb;21(2):220-32. doi: 10.1634/theoncologist.2015-0322. Epub 2015 Dec 14. Review.

17.

Immune checkpoint inhibitors: therapeutic advances in melanoma.

Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S.

Ann Transl Med. 2015 Oct;3(18):267. doi: 10.3978/j.issn.2305-5839.2015.10.27. Review.

18.

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R.

Melanoma Res. 2015 Dec;25(6):486-95. doi: 10.1097/CMR.0000000000000187.

PMID:
26366702
19.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I.

Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25.

20.

Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology.

Buil-Bruna N, Sahota T, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF.

Cancer Res. 2015 Jun 15;75(12):2416-25. doi: 10.1158/0008-5472.CAN-14-2584. Epub 2015 May 4.

21.

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.

Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM).

PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015.

22.

Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.

Lozano MD, Labiano T, Echeveste J, Gurpide A, Martín-Algarra S, Zhang G, Sharma A, Palma JF.

Cancer Cytopathol. 2015 Apr;123(4):230-6. doi: 10.1002/cncy.21513. Epub 2014 Dec 19.

23.

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A.

Clin Chem. 2015 Jan;61(1):297-304. doi: 10.1373/clinchem.2014.230235. Epub 2014 Nov 19.

24.

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Muñoz-Calleja C, Rodríguez-Ruiz M, Sangro B, López-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2014 Nov 15;20(22):5697-707. doi: 10.1158/1078-0432.CCR-13-3203. Epub 2014 Sep 15.

25.

Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.

Berrocal A, Cabañas L, Espinosa E, Fernández-de-Misa R, Martín-Algarra S, Martínez-Cedres JC, Ríos-Buceta L, Rodríguez-Peralto JL.

Adv Ther. 2014 Sep;31(9):945-60. doi: 10.1007/s12325-014-0148-2. Epub 2014 Aug 22. Review.

PMID:
25145549
26.

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S; Spanish Melanoma Group.

Melanoma Res. 2014 Dec;24(6):577-83. doi: 10.1097/CMR.0000000000000108.

27.

Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.

Lozano MD, Labiano T, Zudaire I, Subtil JC, Gúrpide A, Echeveste JI, Zulueta JJ, Martín-Algarra S, Pérez-Gracia JL.

Int J Surg Pathol. 2015 Apr;23(2):111-5. doi: 10.1177/1066896914539551. Epub 2014 Jun 17.

PMID:
24942894
28.

Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma.

Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martín-Algarra S, González A.

Arch Pathol Lab Med. 2014 Jun;138(6):828-32. doi: 10.5858/arpa.2013-0134-OA.

PMID:
24878024
29.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A.

Ann Oncol. 2014 Jul;25(7):1428-36. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25.

PMID:
24769640
30.

A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.

Buil-Bruna N, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF.

AAPS J. 2014 May;16(3):609-19. doi: 10.1208/s12248-014-9600-0. Epub 2014 Apr 17.

31.

MYH polyposis syndrome: clinical findings, genetics issues and management.

Sereno M, Merino M, López-Gómez M, Gómez-Raposo C, Zambrana Tébar F, Moreno Rubio J, Espinós J, Martín-Algarra S, Casado Sáenz E.

Clin Transl Oncol. 2014 Aug;16(8):675-9. doi: 10.1007/s12094-014-1171-0. Epub 2014 Mar 19. Review.

PMID:
24643704
32.

Treatment algorithms in stage IV melanoma.

Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D.

Am J Ther. 2015 Jan-Feb;22(1):61-7. doi: 10.1097/MJT.0b013e31829e885c. Review.

33.

Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.

Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Lozano MD, Echeveste JI, Pérez Gracia JL, Alegre E, Carranza O, Zubiri L, Martín-Algarra S, González A.

Clin Chim Acta. 2014 Feb 15;429:168-74. doi: 10.1016/j.cca.2013.11.034. Epub 2013 Dec 9.

PMID:
24333389
34.

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, Santos-Briz A, Arance A, Lozano MD, Berrocal A, Ríos-Martín JJ, Espinosa E, Rodríguez-Peralto JL; Spanish Society of Pathology; Spanish Society of Medical Oncology.

Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094-013-1090-5. Epub 2013 Oct 16.

PMID:
24129426
35.

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I.

J Immunol. 2012 Oct 1;189(7):3299-310. Epub 2012 Aug 27.

36.

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB.

Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25.

PMID:
22735384
37.

Advances in cutaneous melanoma.

Espinosa E, Berrocal A, López Martín JA, González Cao M, Cerezuela P, Mayordomo JI, Martín Algarra S; Grupo Español de Melanoma (GEM).

Clin Transl Oncol. 2012 May;14(5):325-32. Review.

PMID:
22551537
38.

A new era in the treatment of melanoma: from biology to clinical practice.

Márquez-Rodas I, Martín Algarra S, Avilés Izquierdo JA, Custodio Cabello S, Martín M.

Clin Transl Oncol. 2011 Nov;13(11):787-92. doi: 1007/s12094-011-0734-6. Review.

PMID:
22082642
39.

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I.

J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2.

40.

Evaluation of multiple serum markers in advanced melanoma.

Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A.

Tumour Biol. 2011 Dec;32(6):1155-61. doi: 10.1007/s13277-011-0218-x. Epub 2011 Aug 20.

PMID:
21858537
41.

Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam radiotherapy.

San Miguel I, San Julián M, Cambeiro M, Fernández Sanmamed M, Vázquez-García B, Pagola M, Gaztañaga M, Martín-Algarra S, Martinez-Monge R.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e529-39. doi: 10.1016/j.ijrobp.2011.04.063. Epub 2011 Jun 12.

PMID:
21665380
42.

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

Lozano MD, Zulueta JJ, Echeveste JI, Gúrpide A, Seijo LM, Martín-Algarra S, Del Barrio A, Pio R, Idoate MA, Labiano T, Perez-Gracia JL.

Oncologist. 2011;16(6):877-85. doi: 10.1634/theoncologist.2010-0155. Epub 2011 May 14.

43.

[Identification of the lymph node drainage and selective sentinel lymph node biopsy in a patient with amelanotic melanoma of the uvula].

Domínguez-Prado I, Rodríguez-Fraile M, Alcalde JM, de Abajo J, Martín-Algarra S, García-Velloso MJ.

Rev Esp Med Nucl. 2011 Sep-Oct;30(5):325-6. doi: 10.1016/j.remn.2011.03.006. Epub 2011 Apr 27. Spanish. No abstract available.

44.

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.

Suarez N, Alfaro C, Dubrot J, Palazon A, Bolaños E, Erro L, Hervas-Stubbs S, Martinez-Forero I, Morales-Kastresana A, Martin-Algarra S, Sangro B, Lecanda F, Perez-Gracia JL, Gonzalez A, Melero I.

Int J Cancer. 2011 Jul 15;129(2):374-86. doi: 10.1002/ijc.25681. Epub 2010 Nov 16.

45.

Nonreferral of possible soft tissue sarcomas in adults: a dangerous omission in policy.

Abellan JF, Lamo de Espinosa JM, Duart J, Patiño-García A, Martin-Algarra S, Martínez-Monge R, San-Julian M.

Sarcoma. 2009;2009:827912. doi: 10.1155/2009/827912. Epub 2009 Dec 31.

46.

Long-term results after resection for bone sarcoma pulmonary metastases.

García Franco CE, Torre W, Tamura A, Guillén-Grima F, San-Julian M, Martin-Algarra S, Pardo FJ.

Eur J Cardiothorac Surg. 2010 May;37(5):1205-8. doi: 10.1016/j.ejcts.2009.11.026. Epub 2009 Dec 22.

PMID:
20022760
47.

Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Palma JA, Martín-Algarra S.

J Neurooncol. 2009 Sep;94(2):279-81. doi: 10.1007/s11060-009-9848-x. Epub 2009 Mar 6.

PMID:
19266164
48.

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.

Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L.

Eur J Cancer. 2009 Mar;45(5):732-5. doi: 10.1016/j.ejca.2008.12.005. Epub 2009 Jan 29.

PMID:
19186051
49.

Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.

Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban González E, Martín Algarra S.

Clin Transl Oncol. 2009 Jan;11(1):35-40.

PMID:
19155202
50.

Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.

González-Cao M, Viteri S, Díaz-Lagares A, González A, Redondo P, Nieto Y, Espinós J, Chopitea A, Ponz M, Martín-Algarra S.

Oncology. 2008;74(1-2):12-6. doi: 10.1159/000138351. Epub 2008 Jun 9.

PMID:
18536525

Supplemental Content

Loading ...
Support Center